Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Akari Therapeutics PLC AKTX

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

NDAQ:AKTX - Post Discussion

Akari Therapeutics PLC > Rumour Mill Whispers..
View:
Post by InsideTweeter on Dec 11, 2021 5:56pm

Rumour Mill Whispers..

Watch this..!! 

  • Market cap $75M - Robust Pipeline - Acquisition value of similar companies in complement space with similar pipelines in the $1-2B+ range
  • 2 Phase 3 trials underway (fasttrack and orphan designations)
  • Eye data expected - $6-8B+ market
  • Whispers of multiple business developments on the way

 

"OTHER CLINICAL PROGRAMS

Akari Therapeutics is also pursuing other earlier stage programs that are primarily focused on large disease areas with high unmet need and where complement and leukotriene pathways are implicated. For these programs, the Company is using alternative formulations to the subcutaneous delivery of nomacopan including topical, nebulized or long-acting engineered forms, which provide an opportunity for separate partnering options."

Comment by InsideTweeter on Dec 11, 2021 5:58pm
https://investor.akaritx.com/static-files/50c90eba-430c-4e52-b500-9462bb00ada8